Heart failure is a life-threatening disease. Its prevalence is characterized by a slow, steady increase, with unacceptable high mortality. Slowing disease progression is imperative. One of the most active field is the development of novel biomarkers. Biomarkers are used in routine clinical care for diagnosis, monitoring (response to treatment), and risk stratification of patients with heart failure. In this review, we consider in 2 different sections: blood-derived and imaging biomarkers. Finally, we analyze the effect of combining these 2 categories of biomarkers available in heart failure, aiming at understanding whether their role is complementary or subtractive.

Biomarkers and Imaging: Complementary or Subtractive?

Salzano A.;Marra A. M.;D'Assante R.;Arcopinto M.;Bossone E.;Cittadini A.
2019

Abstract

Heart failure is a life-threatening disease. Its prevalence is characterized by a slow, steady increase, with unacceptable high mortality. Slowing disease progression is imperative. One of the most active field is the development of novel biomarkers. Biomarkers are used in routine clinical care for diagnosis, monitoring (response to treatment), and risk stratification of patients with heart failure. In this review, we consider in 2 different sections: blood-derived and imaging biomarkers. Finally, we analyze the effect of combining these 2 categories of biomarkers available in heart failure, aiming at understanding whether their role is complementary or subtractive.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/773271
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 11
social impact